+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 19Years +
All Genders
ID06106802

Study of Lazertinib Plus Tepotinib in Patients with EGFR Mutated Non-Small Cell Lung Cancer and MET Amplification After Progression on Lazertinib

Led by Sehhoon Park · Updated on 2026-09-10

47

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the use of a combination of Lazertinib and Tepotinib in patients with advanced non-small cell lung cancer NSCLC who have specific EGFR mutations and whose cancer has progressed after treatment with Lazertinib. This phase II study focuses on patients whose tumors show MET overexpression or amplification, a common resistance mechanism to EGFR-targeted therapies. The study builds on previous research showing promising responses when combining Osimertinib with savolitinib in similar patients. Participants will receive daily doses of Lazertinib 240 mg and Tepotinib 500 mg based on results from MET fluorescence in situ hybridization FISH testing. The study is designed as a single group trial and aims to evaluate the clinical effectiveness of this combination treatment specifically in patients with MET gene amplification. Treatment will continue with close monitoring to assess response. During the study, participants will undergo various assessments including genomic tests from tissue and blood samples, imaging to measure tumor response, and safety evaluations. Researchers will measure outcomes such as objective response rate, progression-free survival, duration of response, disease control rate, and overall survival over an extended period. Participants are expected to comply with study procedures and provide informed consent, with the study planned to continue through 2029.

CONDITIONS

Brief Title

Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment

Research Team

S

Sehhoon Park

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here